Morgan Stanley Iterum Therapeutics PLC Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$0.19 - $0.36 $954 - $1,808	-5,023 Reduced 2.22%	221,207 $44,000
Q2 2022 Aug 15, 2022	SELL	$0.19 - $0.36 $954 - $1,808	-5,023 Reduced 2.22%	221,207 $44,000
Q1 2022 Oct 27, 2022	BUY	$0.31 - $0.45 $1,557 - $2,260	5,023 Added 2.27%	226,230 $81,000
Q1 2022 May 13, 2022	BUY	$0.31 - $0.45 $9,768 - $14,179	31,510 Added 16.18%	226,230 $81,000
Q4 2021 Feb 14, 2022	SELL	$0.39 - $0.74 $102,059 - $193,650	-261,690 Reduced 57.34%	194,720 $76,000
Q3 2021 Nov 15, 2021	BUY	$0.54 - $2.29 $246,461 - $1.05 Million	456,410 New	456,410 $255,000

145

Ticker ITRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,233,400
Market Cap $30.1M
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.